Kymera Therapeutics Stock Today
| KYMR Stock | USD 40.61 0.32 0.79% |
Performance0 of 100
| Odds Of DistressLess than 24
|
Kymera Therapeutics is selling at 40.61 as of the 18th of January 2025; that is 0.79 percent increase since the beginning of the trading day. The stock's lowest day price was 40.48. Kymera Therapeutics has about a 24 % chance of experiencing some form of financial distress in the next two years of operation but has generated negative returns over the last 90 days. The performance scores are derived for the period starting the 19th of December 2024 and ending today, the 18th of January 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 21st of August 2020 | Category Healthcare | Classification Health Care |
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the bodys own natural protein degradation system. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts. The company has 64.77 M outstanding shares of which 8.77 M shares are now shorted by private and institutional investors with about 18.36 trading days to cover. More on Kymera Therapeutics
Moving together with Kymera Stock
Moving against Kymera Stock
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores
Kymera Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| CoFounder Chairman | Dr DPHIL | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Biotechnology, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsKymera Therapeutics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Kymera Therapeutics' financial leverage. It provides some insight into what part of Kymera Therapeutics' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Kymera Therapeutics (KYMR) is traded on NASDAQ Exchange in USA. It is located in 200 Arsenal Yards Boulevard, Watertown, MA, United States, 02472 and employs 184 people. Kymera Therapeutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a current market capitalization of 2.63 B. Kymera Therapeutics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 64.77 M outstanding shares of which 8.77 M shares are now shorted by private and institutional investors with about 18.36 trading days to cover.
Kymera Therapeutics currently holds about 392.31 M in cash with (102.83 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 7.61.
Check Kymera Therapeutics Probability Of Bankruptcy
Ownership AllocationThe majority of Kymera Therapeutics outstanding shares are owned by institutional investors. These third-party entities are usually referred to as non-private investors looking to shop for positions in Kymera Therapeutics to benefit from reduced commissions. Consequently, institutional holders are subject to a different set of regulations than regular investors in Kymera Therapeutics. Please pay attention to any change in the institutional holdings of Kymera Therapeutics as this could imply that something significant has changed or is about to change at the company.
Check Kymera Ownership Details
Kymera Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Driehaus Capital Management Llc | 2024-09-30 | 1.3 M | |
| Geode Capital Management, Llc | 2024-09-30 | 1.1 M | |
| Rock Springs Capital Management Lp | 2024-09-30 | 1 M | |
| Jennison Associates Llc | 2024-09-30 | 797.7 K | |
| Deep Track Capital, Lp | 2024-09-30 | 600.3 K | |
| Woodline Partners Lp | 2024-09-30 | 525.1 K | |
| Eventide Asset Management, Llc | 2024-09-30 | 507.9 K | |
| Avidity Partners Management Lp | 2024-09-30 | 500 K | |
| Morgan Stanley - Brokerage Accounts | 2024-09-30 | 488.1 K | |
| T. Rowe Price Associates, Inc. | 2024-09-30 | 6.6 M | |
| Baker Bros Advisors Lp | 2024-09-30 | 6 M |
Kymera Therapeutics Historical Income Statement
Kymera Stock Against Markets
Kymera Therapeutics Corporate Management
| Jared MD | Chief Officer | Profile | |
| DPhil DPHIL | CoFounder Chairman | Profile | |
| JD Esq | Chief Secretary | Profile | |
| Karen Weisbach | Head Culture | Profile | |
| Juliet BA | Head Research | Profile | |
| Melissa Brody | VP Devel | Profile | |
| Elaine Caughey | Chief Officer | Profile |
Additional Tools for Kymera Stock Analysis
When running Kymera Therapeutics' price analysis, check to measure Kymera Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kymera Therapeutics is operating at the current time. Most of Kymera Therapeutics' value examination focuses on studying past and present price action to predict the probability of Kymera Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kymera Therapeutics' price. Additionally, you may evaluate how the addition of Kymera Therapeutics to your portfolios can decrease your overall portfolio volatility.